Our present review will be limited to a critical evaluation of a few still controversial aspects of platelet transfusion therapy including : 1) Indications for platelet transfusions.
2) Quality controls for platelet preparations.
3) The short term storage of platelets. 4) Preservation of platelets by freezing with DMSO.
5) The problem of platelet alloimmunization. platelets from donor rabbits became extremely reduced. However, donor platelet survival measured after a large infusion of 4 x 1010 freshly prepared platelets was nearly normal during the first 24 hours. In vitro tests proved that the large infusion of allogenic platelets had, by absorption, caused a significant reduction of the serum alloantibody. Non-viable and, even, lyophilized platelets could produce this effect, although to a lesser extent (Fig. 1) . A similar result could be demonstrated also in patients with thrombocytopenia due to bone marrow failure, but alloimmunized to platelets by prior transfusions4~ . In conclusion, in the presence of antiplatelet antibody in the circulation, only large numbers of platelets will produce an effective result on hemostasis.
There is no precise threshold platelet level below which severe hemorrhage will undoubtedly occur although hemorrhage is common with platelet below 5,000 to 10, 000/cu mm. It is, therefore, difficult to justify the concept of prophylactic platelet transfusions particularly in face of the fact that indiscriminate Servival of 51Cr-labelled allogenic platelets after infusion of stored or lyophilized platelets in alloimmunized rabbits Fig. 1 The massive infusion of fresh or stored (nonviable) platelets or of lyophilized platelets from random donor rabbits produced a significant increase in recovery and life span of subsequently infused 51Cr-labeled allogenic platelets in the allosensitized animals. Mean values of four experiments for each curve are here reported.
The shaded area indicates the normal range of platelet survival in 10 experiments (Transfusion, 18; 429435, 1978) .
transfusion of platelets most commonly leads to inability to control bleeding because of alloimmunization. Two recent studies5~ 6) on patients with acute leukemia clearly indicate that there is no documented evidence to the fact that prophylactic platelet transfusions can reduce the incidence of bleeding deaths, number of red cell transfusions, incidence of remission and length of survival.
We prefer, therefore, to discourage this practice accepting, however, reasonable exceptions for patients in whom there are clear signs of imminent, overt bleeding related to the platelet deficiency.
Our current recommendations for platelet transfusions are the following : 1)
To transfuse patients with severe hemorrhage or signs of impending hemorrhage, (persistent headache, eye hemorrhages, hematuria, melena, hematemesis, rapidly increasing purpura while platelet counts are less than 10,000/mm3, and in preparation for surgery).
2) To use 5-10 units per transfusion.
3) Immunologic thrombocytopenia is no valid reason for avoiding platelet transfusions.
4) In case of immunologic thrombocytopenia or alloimmunization, to transfuse [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] units at once to adsorb antibody. 5) Old platelets or lyophilized platelets can also be used for antibody absorption, after which 5-10 units of fresh platelets must be infused.
Quality Controls for Platelet Preparations
Measuring the clinical effectiveness of transfused platelets in bleeding patients is a very difficult task because there are many factors which can influence the result of platelet transfusion in a given patient independently of the good quality of the platelet preparation used. These difficulties, however, do not justify the present complacency of clinicians towards blood banks and blood centers. We must admit that quality controls for platelet preparations are, at present, grossly inadequate. Most blood centers limit themselves to examine their platelet concentrates by platelet counting performed at regular or irregular intervals. Our recent spot-check on 60 random platelet concentrates from a non-specified Blood
Center in the United States, gave a mean value of 3.39 x 1010 platelets per unit with a S.D. of 1.43 x 1010 and a range varying from 0.8 to 7.1 x 1010. Usually, the lowest acceptable limit for platelets collected from a unit of 450 ml of blood is 5.5 x 1010. Only 8 % of the platelet concentrates examined were above that limit.
In the future, in addition to the number, the quality of the platelets to be transfused will have to be examind and, also, their hemostatic effect on the bleeding patient. There are a variety of tests which could lend themselves to an effective system of quality control for platelet preparations. One group of tests to be performed on the patient could include one or more of the following :
1) increment in platelet count, 2) platelet survival by labeling with 51Cr,and 3) post-infusion bleeding time by template. The second category to be performed on the platelet concentrates could include: 1) platelet number, 2) platelet aggregation with ADP, collagen, epinephrine, thrombin, ristocetin, 3) in vitro uptake or release of 14C-labeled serotonin, 4) Ca++ uptake or release, 5) platelet content of ATP, ADP, AMP, 6) platelet factor 3, 7) platelet factor 4, and 8) the in vitro platelet response to hypotonic shock (platelet reversal reaction).7) 8)
Which combination of tests will be the most practical and accurate in assuring efficacy of platelet preparations is still unknown. The platelet reversal reaction appears to be the most promising in vitro test for preserved platelets (Fig, 2) .
Large scale studies on this subject are warranted.
The Short Term Storage of Platelets
It was first realized in 1960 that human platelets stored at 4°C partially lost viability within less than three hours, and that after 24 hours of storage at this temperature, most of the platelets were non-viable and, therefore, not effective on hemostasis. Compared with fresh platelets, less than 50 per cent of the stored platelets would reappear in the circulation after infusion, and survived only 2.5 rather than the normal 8.5 days. 9) These findings focused attention on the problem of platelet preservation. Since then, progress has been slow, but significant. The skyrocketing demand for platelet transfusions in the treatment of patients with thrombocytopenic hemorrhage, has exerted a sense of urgency on this complex field.
In this area of research three milestones deserve special mention 1) The introduction by Aster and Jandl, in 1964, of ACD as the anticoagulant of choice for platelet collection and separation.10) This greatly improved the in vivo recovery value of platelets after infusion and, to a smaller extent, the recovery value and the life span of platelets stored for short intervals at 4C." It was seen that the mean recovery value for ACD platelets stored for 24 hours, was nearly one half of the mean value for fresh platelets, while with stored EDTA platelets only one third (35 %) of the respective fresh platelet value was obtained.
2) The finding by Murphy and Gardner, in 1969 , that viability of platelets during storage is better maintained at 22C rather than at 4C12) represents the second milestone. Fig, 3 reports our experience in this field of study. After 48 hours of storage at 22C, platelets had an almost insignificant reduction in survival. The rather dramatic difference in survival values of 22C platelets clearly indicated that platelet viability for transfusion purposes is best maintained at 22C rather than at 4C.
3) The third milestone is represented by the finding of a successful method of platelet preservation by freezing using dimethylsulf oxide (DMSO) as a cryoprotective agent. By this method, platelets can be preserved viable for indefinite periods of time. [13] [14] [15] Storage of platelets at 22C currently represents the easiest and most widely used method of preserving viable platelets for short intervals. However, at 22C the platelets appear to partially lose several functions. In our experiments, after 24 hours of storage, platelet aggregation with ADP was only one third of the value obtained before storage.
Collagen induced aggregation was two thirds of that value. However, recirculation appears to lead to recuperation of this function and after infusion in thrombocytopenic patients, hemostasis becomes cor- While most blood centers and blood banks are presently processing and storing platelets for up to 72 hours at 22C, it should be realized that after 72 hrs at this temperature platelets have a mean, in vivo recovery value which is always less than one half the value obtained with fresh platelets and survival is usually less than 6 days. Furthermore, the platelet survival curves obtained after 72
hrs of storage are mostly exponential.21) Viability of these platelets is, therefore, drastically reduced to such values that one wonders whether arrest of hemorrhage can be obtained with these platelets and how many units should be infused to obtain a significant result in a bleeding patient. Furthermore, if the platelet concentrate contains too many white cells or too little plasma (<50 ml), the pH may drop to < 6 during the 72 hrs. In this case, the platelets would have no viability after infusion and, therefore, no effect on hemostasis. Platelet function is also drastically reduced after this period of storage. All considered,
we strongly discourage the use of platelets stored at 22C for as long as 72
hrs unless each uniti s accurately examined and tested before infusion.
It is obvious that no matter what method or temperature is used to store platelets, injuries are sustained by the cells which reduce their viability and/or their function. Underlying causes and mechanisms operative in the production of these preservation injuries are largely unknown. Corrective actions have so far been empyrical and have lead to only partial success. Presently, research on platelet preservation has reached an impasse probably because all the empyrical "strikes" have been exhausted. Now, therefore, we must go back to the work-bench. We believe that a deeper understanding of the basic biochemical and biophysical mechanisms which assure cellular integrity and functional competence of fresh and stored platelets is essential for any further progress in this field. With regard to platelet preservation, membrane structure, organization and function constitute an important area of platelet research in which our present knowledge must be considered rudimentary. This field appears to us of greatest importance for cell preservation in general and platelet storage in particular.
Platelet Storage by Freezing with DMSO
Freezing platelets with dimethylsulf oxide (DMSO) has become feasible during the past eight years yielding platelet preparations which, compared with fresh platelets, display only a moderately decreased aggregation. This defect, however, appears to rapidly improve upon infusion in vivo. 22) In our experiments, the radioactive 51Cr label was added to the platelets before freezing and viability of the platelets was measured by autologous survival using the 51Cr label. The peak recovery value of platelet radioactivity in the circulation was on the average 63 % (normal, 66 %). The survival time was normal or nearly so in all experi- The increment values obtained soon after infusion were the highest and were decreased 3 hr and, even more, 24 hr postinfusion. Shortening of the bleeding time in the thrombocytopenic patients soon after platelet infusion was of a promptness and degree almost similar to that usually obtained with freshly prepared platelets. The effect of the infused platelets on hemostasis was more pronounced 3 hr than 15 min after infusion, while increments in platelet count were highest soon after infusion. This discrepancy between increase in platelet count and effect on shortening of the bleeding time is not seene with fresh platelets and indicates to us that the frozen platelets carried a functional lesion which temporarily impaired their hemostatic effectiveness without shortening their survival. Three hours post-infusion, increments in platelet count were lower, but shortening of bleeding time was more pronounced, clearly indicating that the platelets were recovering from the storage lesion.
Analysis of the individual results showed no difference between platelets stored for 1 day and those stored for 2-4 days at -79C, and those stored for 9 to 15 months at -85C (three cases represented in Fig. 4 by squares), indicating that freezing and thawing per se rather than length of storage, were responsible for the platelet damage. After thawing, however, the previously frozen platelets could not withstand storage without loss of viability for more than 6 hours.
Their shelf life at room temperature was, therefore, very limited. Frozen platelets will most probably be made available to our hospitals in the future. We believe, however, that frozen platelets will never replace the use of fresh and liquid stored platelets because of practicality and cost. A few indications of frozen platelets seem important to us : 1) Platelets could be harvested and stored for long intervals as a byproduct of blood banking. Presently, about The patients (1, 2, and 3) with acute myeloblastic leukemia were subjected to autologous platelet transfusion.
The patient's own platelets collected during remission were stored by freezing and were infused during recurrence of the disease when there was severe thrombocytopenia.
Periods of storage were 3 months for patient No. Shadowed area represents survival curves of autologous platelets collected from 9 normal healthy volunteers and stored for 3 -7 days by freezing. 25 per sent of the harvested platelets are wasted after 72 hrs of storage at 22C.
2) HL-A typed and matched platelets could be harvested and preserved for long intervals for use in compatible recipients. 3) Autologous platelet transfusions could also be utilized by freezing the patient's own platelets collected by cell separator prior to the occurrence of thrombocytopenia, e.g. in patients scheduled to receive chemotherapy for a malignant process (Fig. 5) .25) Finally, 4) A national or international pool of frozen platelets could be organized and stored indefinitely for use in special emergencies, as in case of an atomic disaster.
The Problem of Platelet Alloimmunization
It has long been known that blood platelets are alloantigenic and that repeated blood or platelet transfusions may cause unresponsiveness to subsequent infusions of donor platelets.26) When this refractory state has been reached, no increment in platelet count follows the platelet infusion. Refractoriness to platelets is a serious clinical problem in severely thrombocytopenic patients and has stimulated studies for a number of years. In the early 1960s, the technique of 51Cr labeling for the measurement of allogenic platelet survival in sensitized recipients Cross-skin grafts were rapidly rejected.
After 6 infusions of platelets from the donor twin, the recipient brother showed marked reduction in survival of the infused fraternal platelets.
An infusion of "nonspecific" platelets from an unrelated donor showed an almost normal survival. single donor was also effective against platelets from other donors although "specific" platelets , i.e. platelets from the immunizing donor, often had a shorter life span than "non-specific" platelets from a new, random donor. 5) Thrombocytopenia in the alloimmunized recipients never occurred.
NON-IDENTICAL TWINS WITH
These findings suggested that platelets have a complex antigenic structure with a large variety of antigens being expressed on their surface so that a recipient would probably always lack one or more of the antigens present in the platelets of any donor.
Our studies on a pair of non-identical male twins with "identical" red cell
antigens (28 could be tested), provided the most conclusive information. Their non-identity was confirmed by the rapid rejection of skin crossgraf ts. After 6 infusions of platelets from the donor twin, the recipient brother showed marked reduction in viability of the infused "fraternal" platelets. A subsequent infusion of platelets from another donor showed an almost normal viability (Fig. 6 ).
This experiment confirmed the independence of platelet antigens from red cell antigens. Furthermore, a detailed study of the platelet viability curve obtained in the recipient twin with the first infusion of platelets from the brother showed a significant shortening of the life span of the allogenic platelets. Since the recipient had never received blood or platelet transfusions, the possibility was raised that the skin allograf t had sensitized the recipient twin against the fraternal platelets, and the concept was developed that blood platelets may contain antigens shared by other body tissues. This problem was evaluated by the use of a rabbit model.28> After three skin allograf ts, viability of platelets from the "specific" skin donor was reduced in all experiments (Fig . 7) . Also, a direct relationship between number of skin-allograf is and degree of reduction in the life span of allogenic platelets could be shown. In subsequent experiments,29> rabbits were first sensitized by one intradermal injection of allogenic platelets.
The rejection time of subsequently implanted skin allograf is was, then, determined. In 42 per cent of the platelet-sensitized animals the rejection time of "specific" allograf ts , that is allograf is from the respective platelet donors, was significantly shortened, i.e. below the limit of 2 S.D. from the mean value observed in non-immunized rabbits. "Nonspecific" allograf ts, i.e. allograf is obtained from animals other than the platelet donors, were also rejected sooner than normal, but in only 10 per cent of the animals. When rabbits were sensitized by one skin allograf t, the rejection time of the second allogaf t was, as expected, shorter than in practically all experiments.
Two results were particularly relevant : that after alloimmunization with "pure" platelets, a significant number of animals displayed a second-set type of rejection of allogenic skin and that the rejection was more evident for "specific" than for "non -specific" grafts.
It was concluded that: 1) Blood platelets and skin have antigens in common. 2) These antigens are not completely individual specific
3) Blood platelets contain histocompatibility antigens. On this evidence, we predicted in 1961, that reduced viability of allogenic platelets and, therefore, reduced effect on hemostasis would potentially be an inevitable event in patients receiving repeated blood or platelet transfusions.
A number of group specific platelet alloantigens have been described since 1957, when Moulinier30) defined antigen "Duzo" using an exceptional antibody from a mother whose infant had neonatal purpura. These antigens, the "Zw", Fig. 7 After sensitization of rabbits by 3 skin homografts, allogenic platelets had a short survival which was shorter when "specific" platelets were used, i.e. platelets from the skin donor. We believe that a simple and reliable method has now been obtained which may be of particular value in detecting alloimmunization to platelets, and in screening platelet donors for alloimmunized patients, even when HLA testing may show a mismatch between donor and recipient.
In conclusion: 1) Platelet alloimmunization with refractoriness to platelet transfusions is inevitable with continued exposure to allogenic platelets, except in rate unpredictable cases of non-responders. Although expensive, the program is feasible.
